(Q84791232)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Grade 3/4 Dermatitis in Head and Neck Cancer Patients Treated With Concurrent Cetuximab and IMRT (English)

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

21 June 2024

1 reference

1 reference

1 reference

head and neck carcinoma

1 reference

Gabriela Studer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Michelle Brown

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Eveline Barata Salgueiro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Hildegard Schmückle

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Natalie Romancuk

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Gisela Winkler

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Soon Jae Lee

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Ariane Sträuli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Beatrix Kissling

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Reinhard Dummer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Christoph Glanzmann

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20732757

21 June 2024

publication date

21 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

11 February 2020

https://api.elsevier.com/content/article/PII:S0360301610006978?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

https://api.elsevier.com/content/article/PII:S0360301610006978?httpAccept=text/plain

21 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

International Journal of Radiation Oncology Biology Physics

21 June 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

110-117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

11 February 2020

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

21 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

21 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm

21 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Severe cutaneous reaction during radiation therapy with concurrent cetuximab

21 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Cetuximab is effective, but more toxic than reported in the Bonner trial

21 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes

21 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer.

21 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab

21 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Acneiform rash secondary to cetuximab plus head and neck radiotherapy

21 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab

21 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck

21 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients

21 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Determination and delineation of nodal target volumes for head-and-neck cancer based on patterns of failure in patients receiving definitive and postoperative IMRT.

21 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Determining optimal clinical target volume margins in head-and-neck cancer based on microscopic extracapsular extension of metastatic neck nodes

21 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

21 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial

21 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial

21 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy

21 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study

21 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer

21 June 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma

21 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.IJROBP.2010.05.018

21 June 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20732757%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference